Where are we going with SSRIs?
by
Isaac M
Psychopharmacology Evaluation Unit,
University Hospital,
Lewisham, London, UK.
misaac@stekel.demon.co.uk
Eur Neuropsychopharmacol 1999 Jul; 9 Suppl 3:S101-6

ABSTRACT

During the past decade the selective serotonin reuptake inhibitors (SSRIs) have become established as the treatment of choice for depression. As newer antidepressants become available on the market, it is important to reappraise the position of the SSRIs in the management of depression. This review will address the question: where are we going with the SSRIs? The continued establishment of the SSRIs as first-line treatment for depression will be discussed, focusing on the more rapid onset of antidepressant efficacy seen with pindolol augmentation and the use of SSRIs for treatment of depression in patients with physical illnesses, particularly ischaemic heart disease. The SSRIs have well-documented efficacy in panic disorder and obsessive-compulsive disorder, and paroxetine has recently been licensed for social anxiety disorder/social phobia in some countries. Results will be presented from studies with the SSRIs in new therapeutic areas, including post-traumatic stress disorder and generalized anxiety disorder.

SSRIs
Sertraline
Fluoxetine
Citalopram
Paroxetine
Fluvoxamine
Drugs and sex
SSRIs compared
SSRI suicide link?
5-HT1b and aggression
Antidepressant mechanisms
Neuropharmacology of serotonin
5-HT-moduline, serotonin and mood
Types of depression and mood-disorder
Antidepressant use by American children
Are SSRI antidepressants little better than placebos?

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family